Ranked 10th on Forbes magazine’s 2016 list of the “World’s Most Innovative Companies”, biotechnology company BioMarin will continue to grow its workforce in Ireland over the coming years.
This is the third consecutive year that BioMarin has ranked in the top 10, acknowledging the company’s ongoing commitment to delivering first-in-class or best-in-class therapies for those with severe or life-threatening rare diseases.
BioMarin entered Ireland in August 2011 and since then it has announced significant expansion plans. BioMarin initially announced the creation of 100 jobs in 2011, but, as a result of global demand for its products, further job creation was announced early in 2014.
In mid-2014, BioMarin announced expansion plans for its Dublin operation, with the creation of up to 50 new jobs in its Dublin Global Commercial Operations Hub.
BioMarin continues to expand its workforce with 2016 alone seeing the recruitment of over 100 people in Ireland.
The global biotech company is now looking to fill positions across a range of departments, including manufacturing, manufacturing sciences and technology, engineering and maintenance, quality control, quality assurance, as well as in validation, supply chain, logistics, warehouse, and finance.
Speaking about the workforce expansion, Michael O’Donnell, site leader at BioMarin in Cork, says: “Cork is the hub for BioMarin’s European manufacturing operations, and Ireland is a strategic location for BioMarin’s growth in global operations. Ireland provides a highly educated, well-trained and experienced workforce and business-friendly climate, along with a strong governmental support model. This allows us to focus on what we do best: Targeting diseases, like Morquio A syndrome, an ultra-rare, severely debilitating disease that lacks effective drug therapies and affects relatively few people worldwide, many of whom are children.”
For nearly 20 years, BioMarin has been committed to making a big impact in the lives of small patient populations. The company remains steadfast in its original mission: To bring new treatments to market that will make a big impact on small patient populations.
Founded in San Rafael, San Francisco, BioMarin has developed and commercialised five products since 1997, including an enzyme- replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder.
Two additional products are scheduled for manufacturing over the next year in Shanbally, with plans to add more in the coming years.
One of BioMarin’s differentiating factors in attracting talent has been its connection with patients with rare diseases, explains O’Donnell: “We have had many patients visit and speak to the team about the impact our treatments have made to their lives. It gives our employees a compelling reason to come to work.”
At BioMarin, employees have the opportunity to work in multiple areas of the business. In terms of career progression, hiring managers seek out talent with the right attitude and approach to fit the organisational culture.
O’Donnell says: “We invest significantly on the importance of ‘how we work’, as much as recognising the technical aptitude a person may bring to their role.
“Performance is rewarded with providing opportunities to get involved cross-functionally, or to transition to different areas across the business on an assignment or rotational basis. Over time, there are opportunities to work globally, in the US and in Europe.”
n For more information on current vacancies in BioMarin visit online at:
© Irish Examiner Ltd. All rights reserved